Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glesatinib, Sitravatinib or Mocetinostat + Nivolumab in NSCLC
NCT02954991Phase 2Terminated
- Sponsor
- Mirati Therapeutics
- Start
- Nov 2016
- Primary completion
- Nov 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of glesatinib, sitravatinib and mocetinostat in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Mirati Therapeutics. Primary endpoint: Objective Response Rate up to 40.6 months. Started Nov 2016; status: terminated.
02
Drugs
glesatinibsitravatinibmocetinostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02954991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954991.